Actively Recruiting
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Melanoma and Epithelial Cancers
Led by Hadassah Medical Organization · Updated on 2025-10-02
50
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a new approach to stimulate the immune response in patients with metastatic cancers, including melanoma, colorectal, gastric, ovarian, breast, lung, and kidney epithelial cancers. This study is based on modifying tumor cells grown in the laboratory to make them stimulatory to the immune system. The goal is to assess whether this treatment can prolong survival in patients with these advanced cancers. The treatment involves injecting patients with tumor cells that have been modified and irradiated to kill them. Patients will receive five vaccine doses, each given subcutaneously at three-week intervals. These doses consist of irradiated and DNP-conjugated tumor cells, designed to activate the immune system against the cancer. Participants will be involved in receiving the vaccine injections at specified intervals. They must meet specific health criteria, including certain blood counts and organ function levels. Throughout the study, patients will be monitored for their clinical performance and response to the treatment. The study expects to follow participants and evaluate their health outcomes over time, with the overall aim of measuring the treatment's impact on survival and immune activation.
CONDITIONS
Brief Title
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosed with metastatic melanoma, breast, ovary, colorectal, gastric, lung, or kidney cancer
- Have failed at least one chemotherapy protocol
- Clinical performance status of ECOG 0 or 1
- Absolute neutrophil count greater than 1000/mm3
- Serum ALT and AST levels less than three times the upper limit of normal
- Serum creatinine less than or equal to 1.6 mg/dl
- Able to understand and sign the informed consent document
You will not qualify if you...
- Younger than 18 years of age
- Pregnant women
- Life expectancy of less than three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 12 weeks
Participants receive five vaccine doses composed of irradiated and DNP-conjugated tumor cells, injected subcutaneously at 3-week intervals.
5 injection visits spaced 3 weeks apart
Trial Site Locations
Total: 1 location
1
Hadassah Medical Organization
Jerusalem, Israel, 91120
Actively Recruiting
Research Team
H
Hani Steinberg, R.N. B.A.
T
Tamar Peretz, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here